Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/136354
Full metadata record
DC FieldValueLanguage
dc.creatorPeixoto, A
dc.creatorRelvas-Santos, M
dc.creatorAzevedo, R
dc.creatorSantos, LL
dc.creatorFerreira, JA
dc.date.accessioned2021-09-20T10:53:24Z-
dc.date.available2021-09-20T10:53:24Z-
dc.date.issued2019
dc.identifier.issn2234-943X
dc.identifier.urihttps://hdl.handle.net/10216/136354-
dc.description.abstractDecades of research have disclosed a plethora of alterations in protein glycosylation that decisively impact in all stages of disease and ultimately contribute to more aggressive cell phenotypes. The biosynthesis of cancer-associated glycans and its reflection in the glycoproteome is driven by microenvironmental cues and these events act synergistically toward disease evolution. Such intricate crosstalk provides the molecular foundations for the activation of relevant oncogenic pathways and leads to functional alterations driving invasion and disease dissemination. However, it also provides an important source of relevant glyco(neo)epitopes holding tremendous potential for clinical intervention. Therefore, we highlight the transversal nature of glycans throughout the currently accepted cancer hallmarks, with emphasis on the crosstalk between glycans and the tumor microenvironment stromal components. Focus is also set on the pressing need to include glycans and glycoconjugates in comprehensive panomics models envisaging molecular-based precision medicine capable of improving patient care. We foresee that this may provide the necessary rationale for more comprehensive studies and molecular-based intervention.
dc.description.sponsorshipThe authors wish to acknowledge the Portuguese Foundation for Science and Technology (FCT) for the human resources grants: PhD grant SFRH/BD/111242/2015 (AP), and FCT auxiliary researcher grant CEECIND/03186/2017 (JF). FCT is co-financed by European Social Fund (ESF) under Human Potential Operation Programme (POPH) from National Strategic Reference Framework (NSRF). The authors also acknowledge the Portuguese Oncology Institute of Porto Research Centre (CI-IPOP-29-2014; CI-IPOP-58-2015), the PhD Program in Biomedical Sciences of ICBAS-University of Porto, and the Early stage cancer treatment, driven by context of molecular imaging (ESTIMA) framework (NORTE-01-0145-FEDER-000027). The authors were also supported by the CANCER project (NORTE-01-0145-FEDER-000029) co-funded through the NORTE-45-2015-02.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofFrontiers in Oncology, vol.9:380
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectCancer
dc.subjectCancer hallmarks
dc.subjectGlycans
dc.subjectMicroenvironment
dc.subjectProtein glycosylation
dc.titleProtein glycosylation and tumor microenvironment alterations driving cancer hallmarks
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.3389/fonc.2019.00380
dc.relation.publisherversionhttps://www.frontiersin.org/articles/10.3389/fonc.2019.00380/full
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.3389-fonc.2019.00380.pdf3.53 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons